Acquisition Opportunity Leverage the recent acquisition by Yuhan USA as a gateway to cross-sell PROGEN antibody and AAV tools to Yuhan's distribution and customer base, expanding market reach in North America and Asia.

AAV Growth Capitalize on PROGEN’s leadership in AAV analytical tools and Simple Plex AAV assays by targeting gene therapy developers seeking reliable capsid quantification and titer solutions for clinical and commercial programs.

Strategic Partnerships Highlight and upsell collaboration opportunities with Thermo Fisher Scientific and Bio-Techne to access broader distribution networks, co-development of assays, and bundled offerings for antibodies and gene therapy reagents.

Integrated Toolkits Position PROGEN as a one-stop shop for gene therapy toolkits including AAV reagents, LNP delivery kits, antibodies, and proteins to streamline researchers’ workflows and reduce vendor fragmentation.

Global Expansion Explore partnerships or distributor agreements in Europe and North America to scale presence among academia and biotech startups, leveraging PROGEN’s long-standing experience as a pioneering German biotech company.